US20080110792A1 - Methods for administering weight loss medications - Google Patents

Methods for administering weight loss medications Download PDF

Info

Publication number
US20080110792A1
US20080110792A1 US11/937,367 US93736707A US2008110792A1 US 20080110792 A1 US20080110792 A1 US 20080110792A1 US 93736707 A US93736707 A US 93736707A US 2008110792 A1 US2008110792 A1 US 2008110792A1
Authority
US
United States
Prior art keywords
unit dosage
drug
package
dosage package
zonisamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/937,367
Other languages
English (en)
Inventor
Anthony McKinney
Gary Tollefson
Eckard Weber
Rick Soltero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39402403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080110792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US11/937,367 priority Critical patent/US20080110792A1/en
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Assigned to OREXIGEN THERAPEUTICS, INC. reassignment OREXIGEN THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCKINNEY, ANTHONY, TOLLEFSON, GARY, WEBER, ECKARD, SOLTERO, RICK
Publication of US20080110792A1 publication Critical patent/US20080110792A1/en
Priority to US12/838,364 priority patent/US8722085B2/en
Priority to US14/220,349 priority patent/US9125868B2/en
Priority to US14/844,476 priority patent/US20160193152A1/en
Assigned to U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: OREXIGEN THERAPEUTICS, INC.
Priority to US16/101,853 priority patent/US10307376B2/en
Priority to US16/428,069 priority patent/US20190282503A1/en
Priority to US16/938,443 priority patent/US20200352863A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs

Definitions

  • This invention relates to methods for administering pharmaceutical compositions, preferably, but not limited to, compositions that are useful for affecting weight loss, suppressing appetite and/or treating obesity-related conditions in individuals.
  • Obesity is a disorder characterized by the accumulation of excess fat in the body. Obesity has been recognized as one of the leading causes of disease and is emerging as a global problem. Increased instances of complications from obesity, such as hypertension, non-insulin-dependent diabetes mellitus, arteriosclerosis, dyslipidemia, certain forms of cancer, sleep apnea and osteoarthritis, have been related to increased instances of obesity in the general population.
  • Various methods of treating diseases or conditions involve administering certain drugs or combinations thereof.
  • a number of references disclose the administration of certain weight loss formulations that include an anticonvulsant, an opioid antagonist and/or a norepinephrine reuptake inhibitor (NRI) to a patient in need thereof to affect weight loss.
  • NRI norepinephrine reuptake inhibitor
  • 2004/0033965; 2004/0198668; 2004/0254208; 2005/0137144; 2005/0143322; 2005/0181070; 2005/0215552; 2005/0277579; 2006/0009514; 2006/0142290; 2006/0160750 and 2006/0079501 all of which are hereby incorporated by reference in their entireties.
  • administering an anticonvulsant in combination with an antidepressant may provide a combination having an enhanced ability to affect weight loss, but does not necessarily reduce or eliminate the initial adverse side effects that may accompany the administration of the anticonvulsant.
  • administration of an opioid receptor antagonist in combination with an antidepressant may provide a combination having an enhanced ability to affect weight loss, but does not necessarily reduce or eliminate the adverse side effects that may accompany administration of the opioid antagonist.
  • these methods and systems involve altering the dosage of one or more components of a multi-component formulation during the course of administration. For example, in an embodiment, the dose of one drug in a two-drug weight loss formulation is gradually increased from an initial low dose to an effective maintenance dose during subsequent administrations. In preferred embodiments, adverse side effects are reduced, and patient compliance and comfort are increased, thereby increasing the efficacy of the treatment regimen.
  • An embodiment provides a method of treating a disease or condition, for example, affecting weight loss, suppressing appetite and/or treating an obesity-related condition.
  • the method comprises administering to a patient in need thereof a first dosage including a first drug and a second drug; and administering a second dosage comprising the first drug and the second drug, wherein the second dosage includes a different amount of the second drug than the first dosage.
  • the unit dosage package comprises a first unit dosage including a first drug and a second drug; a second unit dosage comprising the first drug and the second drug, wherein the second unit dosage comprises a different amount of the second drug than the first unit dosage; and a unit dosage package configured to hold the first unit dosage and the second unit dosage.
  • Another embodiment provides a method of packaging a combination of bupropion and at least one of zonisamide and naltrexone.
  • the method comprises providing a unit dosage package that holds the bupropion and the at least one of the zonisamide and the naltrexone; and packaging administration instructions with the unit dosage package in a unit dosage package.
  • FIG. 1A is a front perspective of unit cells in an embodiment of a unit dosage package.
  • FIG. 1B is a back perspective of unit cells in an embodiment of a unit dosage package.
  • FIG. 1C is a back perspective of unit cells in an embodiment of a unit dosage package.
  • FIG. 2A is a front perspective view of an embodiment of a unit dosage package with two rows of unit cells.
  • FIG. 2B is a back perspective of the unit dosage package in FIG. 2A .
  • FIG. 3A is a front perspective of an embodiment of a unit dosage package with two rows of unit cells.
  • FIG. 3B is a back perspective of the unit dosage package in FIG. 3A .
  • FIG. 4A is a front perspective of an embodiment of a unit dosage package showing four rows of unit cells.
  • FIG. 4B is a back perspective of the unit dosage package in FIG. 4A .
  • FIG. 5A is a front perspective of an embodiment of a unit dosage package containing four rows of unit cells within two rows of unit cells.
  • FIG. 5B is a back perspective of the unit dosage package in FIG. 5A .
  • FIG. 6A is a front perspective of an embodiment of a unit dosage package with a second unit dosage package attached.
  • FIG. 6B is a back perspective view of the unit dosage package in FIG. 6A .
  • FIG. 7A is a front perspective of an embodiment of a unit dosage package containing six rows of unit cells and two columns of unit cells.
  • FIG. 7B is a back perspective of the unit dosage package in FIG. 7A .
  • FIG. 8A is a front perspective of an embodiment of a unit dosage package with a second unit dosage package attached.
  • FIG. 8B is a back perspective view of the unit dosage package in FIG. 8A .
  • FIG. 9A is a front perspective view of an embodiment of a unit dosage package containing eight rows of blisters and two columns of unit cells.
  • FIG. 9B is a back perspective view of the unit dosage package in FIG. 9A .
  • rows (horizontal) and columns (vertical) may be inverted so that rows become columns and columns become rows.
  • Such an inversion is within the scope of the present disclosure although as a convention this application generally refers to horizontal as rows and vertical as columns.
  • the preferred embodiments described herein relate generally to systems and methods for administering pharmaceutical compounds for treatment of a disease or condition, (e.g., affecting weight loss, suppressing appetite and/or treating an obesity-related condition), while reducing, minimizing and/or eliminating potential initial adverse side effects on a patient.
  • these methods and systems involve altering the dosage of one or more ingredients of a multi-ingredient pharmaceutical formulation during the course of administration.
  • the dose of one drug in a two-drug weight loss formulation is gradually increased from an initial low dose to an effective maintenance dose during subsequent administrations.
  • adverse side effects are reduced, patient compliance and comfort are increased, and thereby the efficacy of the treatment regimen is increased.
  • a pharmaceutical formulation comprises two or more pharmaceutical compositions administered either as discrete simultaneously administered dosages or as a single dosage form administration comprising two or more active ingredients or pharmaceutical compositions, e.g. a multilayer tablet.
  • a pharmaceutical composition is a mixture of chemical compounds (e.g. one or more drugs) with additional pharmaceutical compounds, such as diluents or carriers.
  • the pharmaceutical composition facilitates administration of the drug to an organism.
  • Pharmaceutical compositions may be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • a “drug” as used herein refers both to active ingredients and formulations that have received FDA approval as well as those that have not received FDA approval.
  • a multilayer tablet is a pharmaceutical formulation comprising two or more pharmaceutical layers comprising pharmaceutical compositions and an intermediate layer between at least two of the two or more pharmaceutical layers.
  • the intermediate layer is configured to dissolve in vivo with a substantially higher dissolution rate than at least two of the two or more pharmaceutical layers.
  • Methods of treating a disease or condition comprise administering a series of dosages to a patient.
  • administering a first dosage comprises administering a first drug and a second drug.
  • Each drug may be administered separately or each drug may be part of a single dosage, e.g., a capsule or multilayer tablet.
  • Multiple techniques of administering a drug exist in the art including, but not limited to, oral, injection, aerosol, parenteral and topical administration.
  • Administration of a second dosage comprises administering the first drug and the second drug.
  • the amount of the second drug in the second administration is different and, in a preferred embodiment, greater than the amount of the second drug in the first administration. In subsequent administrations, the amount of the second drug may be increased until an effective maintenance dose is reached.
  • Some drugs may incur initial and/or severe side effects when administered at an effective maintenance dose.
  • Such drugs may be coupled with other drugs in pharmaceutical compositions to increase the efficacy or tolerability (e.g. by reducing adverse side effects) of one or both drugs.
  • the side effects that might otherwise be present during administration are reduced or eliminated.
  • some pharmaceutical formulations for affecting weight loss, suppressing appetite and/or treating an obesity-related condition while reducing, minimizing and/or eliminating potential initial adverse side effects on a patient include administration of an antidepressant in conjunction with an anticonvulsant and/or an opioid receptor antagonist.
  • the pharmaceutical formulation comprising the antidepressant with the anticonvulsant or the opioid receptor antagonist is effective at treating obesity.
  • a first dosage comprising the antidepressant with the anticonvulsant or the opioid receptor antagonist is administered on a first day.
  • a second dosage comprising the antidepressant with the anticonvulsant or the opioid receptor antagonist is administered on a second day. The amount of the anticonvulsant or the opioid receptor antagonist in the second dosage is increased relative to the first dosage.
  • an amount of the anticonvulsant or the opioid receptor antagonist is increased until a maintenance dosage is reached.
  • the patient may become accustomed to the administration of the dosage of the anticonvulsant or the opioid receptor antagonist present in the pharmaceutical formulation.
  • the patient is then less likely to have initial and/or severe side effects that might otherwise accompany a dosage of the anticonvulsant or the opioid receptor antagonist with the antidepressant in an amount effective to treat obesity related conditions.
  • Unit dosage packages are employed to facilitate the methods described herein.
  • Unit dosage packages comprise pharmaceutical formulations of drugs for treating a disease or condition, preferably for affecting weight loss, suppressing appetite and/or treating an obesity-related condition.
  • Unit dosage packages comprise a first unit dosage comprising a first drug and a second drug, and a second unit dosage comprising the first drug and the second drug. In the second unit dosage, the amount of the second drug is different than the amount of the second drug in the first unit dosage.
  • FIG. 1A illustrates an embodiment of the unit dosage package.
  • FIG. 1A shows a front side 100 of unit cells 104 .
  • Each unit cell 104 contains at least one blister 106 with a cavity that encloses a pharmaceutical composition 118 .
  • the unit cell 104 contains a label 108 for a specific dose (or instructions for administering a unit dosage) contained within the unit cell 104 .
  • the unit cell 104 also optionally comprises a closed push-through tab 110 and optionally a corresponding open push-through tab 114 , which has been pushed from the front side 100 of the unit cell 104 to the back, to open the blister 106 and provide access to the pharmaceutical composition 118 .
  • the tab is not present, and the dosage is pushed through the covering of the blister pack for dispensing.
  • FIG. 1B shows a back side 102 of the unit dosage package.
  • the unit cell 104 in this embodiment has a label 108 for a single dose contained within the unit cell 104 , wherein the label 108 on the back side 102 corresponds to the label 108 on the front side of the unit dosage package 100 .
  • Shown in the embodiment of FIG. 1B is an open push-through tab 114 before it has been peeled back or removed to open the blister 106 .
  • FIG. 1C the back side 102 of the unit dosage package is illustrated with an unopened unit cell 112 contrasted with an opened and peeled back push-through tab 116 that allows dispensing of the pharmaceutical composition 118 from the blister 106 .
  • FIG. 2A is a front side of a unit dosage package 210 attached to a cover 206 .
  • the attached cover 206 folds to cover the front side of the unit dosage package 210 by means of a fold 204 which connects the cover 206 to the unit dosage package.
  • the unit dosage package 210 contains at least one blister 106 with a cavity that protrudes through the front of the unit dosage package 210 .
  • the blisters 106 are thermo-formed or cold-formed blisters.
  • a plurality of the blisters on unit cells is formed into rows such as the row illustrated in FIG. 2A between the arrows 216 or the row between the arrows 208 .
  • a row of blisters 216 corresponds to increasing dosages of a specific pharmaceutical ingredient or composition.
  • a single blister 106 within a row contains a dosage combination of an anticonvulsant and an antidepressant. The amount of the anticonvulsant increases in each dosage from one end of the row 208 to an opposite end, while the amount of antidepressant is constant in every dosage contained in the row 208 .
  • push-through tabs 202 allow for the opening of a single blister 106 in either the row 216 or the row 208 .
  • the push-through tab 202 allows for opening the blister 106 by pushing the tab 202 from the front of the unit dosage package 210 through the back of the unit dosage package using a key, a pen, a pin, a thumbnail or some other object.
  • the unit dosage package is then turned over and the push-through tab 202 is peeled away to expose and/or remove the unit dosage package backing.
  • a dosage otherwise contained within a blister 106 may then be pushed through the backing and out of the back of the unit dosage package. Alternatively, the dosage is pushed through the backing without the optional tab.
  • the blisters can be on the top or bottom, and the dosage correspondingly pushed through the bottom or top of the package.
  • a unit dosage package is made of any suitable material.
  • instructions for opening a unit cell are included on the cover 206 attached to the unit dosage package.
  • instructions are included below the row 208 , the row 216 or on any part of the front of the unit dosage package 210 .
  • instructions are separate from, but included with the unit dosage package as part of a kit. Instructions may also be printed on the packaging that comes with the unit dosage package.
  • instructions say something along these lines: (1) push-through black half circle with a key, a pen or a thumbnail; (2) turn card over and peel tab to expose foil; (3) push on plastic blister to dispense.
  • the text “PUSH” or some variation thereof is located on the tabs which open the blisters.
  • FIG. 2B illustrates the back of a unit dosage package 214 .
  • the back of the unit dosage package 214 is made of any suitable material for a unit dosage package.
  • the backing 212 of each blister 106 may comprise a semi-rigid foil or other material connected to the tab 202 and also to the blister 106 .
  • the tab 202 is then peeled back, peeling away the backing 212 to expose and/or allow for the pharmaceutical composition to be pushed out of the blister 106 .
  • the tab is omitted and the dosage is pushed through the backing without first peeling it back.
  • multiple drugs are contained within a single blister for release at a specific time.
  • a single blister contains only a single drug, for example, a single dose of one or more immediate-release formulations.
  • immediate-release is used herein to specify that the immediate release formulation is not configured to alter the dissolution profile of the formulation.
  • the one or more formulations comprise one or more controlled-release formulations.
  • controlled-release is used herein in its ordinary sense and thus includes formulations that are combined with ingredients to alter their dissolution profile.
  • a “sustained-release” formulation is a type of controlled-release formulation, wherein ingredients have been added such that the dissolution profile is extended over a longer period of time than that of an immediate release formulation.
  • a “unit dosage” is an amount of drug or drugs taken at a single dosage time.
  • a unit dosage comprises a combination of drugs in a single pharmaceutical formulation or physical form, e.g. a pill or capsule.
  • a unit dosage comprises a combination of drugs in a plurality of separate pharmaceutical formulations or physical forms, e.g. multiple pills or capsules.
  • a single drug is present in a plurality of pharmaceutical formulations or physical forms, e.g. pills or capsules, as a single unit dosage.
  • a unit dosage may be contained within one or more blisters.
  • a single blister contains only a single drug, for example, a single dose of sustained-release zonisamide in a single pill or capsule.
  • a unit dosage of sustained-release zonisamide may be contained within multiple blisters, for example, each containing one or more pills.
  • two or three of the blisters within a single row or column in a unit dosage package comprise a single unit dosage of a drug.
  • FIG. 3A illustrates an embodiment wherein a day label 302 corresponds with a time label 304 .
  • the day label 302 additionally corresponds to a unit cell 104 containing a unit dosage.
  • a single blister 106 is contained within a unit cell 104 .
  • a row of blisters 308 corresponds to a specific time label 304 for administration of a medication.
  • a certain day 302 corresponds to a particular administration of one or more unit dosages to a patient. For example, from row 308 and column 306 a first unit dosage corresponds to an AM administration on a Saturday. Later that same day, from row 310 and column 306 (for administration in an evening time), a patient receives a second unit dosage.
  • a patient uses the unit dosage package to administer the particular drugs for affecting obesity.
  • a pharmaceutical composition corresponding to a unit dosage includes a plurality of drugs.
  • a specific day 302 and time 304 corresponds to a single unit dosage.
  • each dosage comprises a static amount of a first drug and a static amount of a second drug.
  • each dosage comprises a static amount of a first drug and varying dosages of a second drug.
  • each dosage comprises a varying amount of a first drug and a varying amount of a second drug.
  • unit dosages on a unit dosage package are sequentially numbered, lettered, or a combination of numbers and letters to indicate an order of administration of each unit dosage.
  • the sequential numbering corresponds to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, . . . n, wherein each number corresponds to a part of, or whole day, week, or month, where “n” is a finite number.
  • a unit dosage package similar in form to FIG. 3A comprises numerical labels corresponding to the days and times of administration. In this embodiment, no “day labels” or “time labels” are present.
  • FIG. 3B illustrates a back of the unit dosage package illustrated in FIG. 3A .
  • FIG. 4A illustrates a series of push-through tabs 402 for opening a plurality of blisters 106 .
  • blisters from both row 404 and row 406 would be opened by pulling on tab 414 to remove a backing 416 discussed below with reference to FIG. 4B .
  • push-through tab 418 would open two blisters 106 within column 412 , one from row 408 and one from row 410 .
  • FIG. 4B illustrates the backing 416 for the unit dosage package in FIG. 4A .
  • the backing 416 allows for a push-through tab 402 to open multiple blisters at a single time.
  • specific day labels 302 on unit cells 104 each correspond to a time label 304 for administration of medication.
  • the time labels 304 shown for administration of medication are AM and PM administrations.
  • a unit cell 104 comprises a single blister 106 from row 502 and a single blister 106 from row 504 .
  • a row of unit cells 104 corresponds to evening administration.
  • each unit cell 104 within row 506 contains two blisters 106 for evening administration of a specific pharmaceutical composition.
  • a unit dosage comprising a combination of drugs within column 508 corresponds to a morning administration and an evening administration on a Saturday.
  • the morning administration comprises one blister 106 from row 502 and one blister 106 from row 504 .
  • the combination of medications from rows 502 , 504 correspond to a unit dosage of medication for administration on a Saturday morning.
  • FIG. 5B illustrates a back of the unit dosage package illustrated in FIG. 5A .
  • FIG. 6A Another embodiment of a unit dosage package is illustrated in FIG. 6A .
  • the embodiment shows a second unit dosage package 602 attached to a first unit dosage package 601 via a fold 610 .
  • the first unit dosage package 601 illustrates a row 604 comprising four blisters 106 wherein a single push-through tab 606 that opens all blisters 106 within the row 604 .
  • the second unit dosage package 602 contains multiple blisters 106 arranged into rows and columns.
  • a push-through tab 612 for opening a row of blisters 106 is shown on the second unit dosage package 602 .
  • the push-through tab 612 would open an entire row, for example, the row 608 on the second unit dosage package 602 .
  • a row of blisters 608 on the second unit dosage package 602 contains two blisters 106 .
  • a row of blisters 604 on the first unit dosage package 601 contains four blisters.
  • a single unit dosage package comprises numerous blisters 106 .
  • each row of blisters 106 is configured to be opened by the push-through tabs 606 or 612 .
  • FIG. 6B corresponds to a back side of the unit dosage package illustrated in FIG. 6A .
  • FIG. 7A Another embodiment of a unit dosage package is illustrated in FIG. 7A . Similar to the embodiment illustrated in FIG. 6A , a first unit dosage package 601 is attached to a second unit dosage package via a fold 610 . The first unit dosage package 601 is also attached to a cover 206 via a fold 204 . In some embodiments the cover comprises an instruction sheet. In this embodiment, the first unit dosage package 601 corresponds to AM administration of unit dosages and the second unit dosage package 602 corresponds to PM administration of unit dosages.
  • FIG. 7B illustrates the back side of the unit dosage package in FIG. 7A .
  • FIG. 8A illustrates one embodiment comprising a first unit dosage package 601 attached to a cover 206 via fold 204 .
  • the first unit dosage package 601 is also attached to a second unit dosage package 602 via fold 610 .
  • the second unit dosage package 602 comprises a row 804 of four blisters 106 wherein a single row of blisters 106 are opened by a single push-through tab 612 .
  • FIG. 8A illustrates that a single push-through tab 612 opens all four blisters 106 within a row 804 on the second unit dosage package 602 .
  • a single push-through tab 606 opens the row 804 of blisters 106 on the first unit dosage package 601 .
  • FIG. 8B illustrates a back of the unit dosage package in FIG. 8A .
  • the first unit dosage package 601 attached to a cover 206 via a fold 204 corresponds to a time label 304 , specifically an AM administration of a drug.
  • the AM dosages for an extra week are arranged in unit cells 104 on the first unit dosage package 601 .
  • opening a single push-through tab 606 exposes drugs contained within a row 604 corresponding to a unit dosage of an AM administration on a Thursday.
  • a push-through tab 612 opens all blisters 106 in a unit cell 104 corresponding to the row 804 on Saturday evening.
  • Each day and time listed on the first unit dosage package 601 and the second unit dosage package 602 corresponds to different dosages.
  • FIG. 9B illustrates the back side of the unit dosage package illustrated in FIG. 9A .
  • the active pharmaceutical ingredients utilized to treat a disease or condition can be selected from any of the compounds below.
  • the compositions for the treatment of obesity or for affecting weight loss comprise an antidepressant and at least one of an anticonvulsant and an opioid receptor antagonist.
  • the antidepressant comprises a dopamine reuptake inhibitor or receptor antagonist.
  • dopamine reuptake inhibitors include phentermine and pharmaceutically acceptable salts or prodrugs thereof.
  • dopamine receptor antagonists include haloperidol, ocaperidone, risperidone, olanzapine, quetiapine, amisulpride, and pimozide and pharmaceutically acceptable salts or prodrugs thereof.
  • the antidepressant comprises a norepinephrine reuptake inhibitor.
  • norepinephrine reuptake inhibitors examples include bupropion, thionisoxetine, atomoxetine and reboxetine and pharmaceutically acceptable salts or prodrugs thereof.
  • Other embodiments include those in which the antidepressant is a dopamine agonist. Dopamine agonists available on the market include cabergoline, amantadine, lisuride, pergolide, ropinirole, pramipexole, and bromocriptine.
  • the antidepressant comprises a serotonin reuptake inhibitor, preferably a selective serotonin reuptake inhibitor (SSRI). Examples of serotonin reuptake inhibitors include fluoxetine and pharmaceutically acceptable salts or prodrugs thereof
  • the term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • Pharmaceutical salts can be obtained by reacting a compound of the disclosure with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • Pharmaceutical salts can also be obtained by reacting a compound of the disclosure with a base to form a salt such as ammonium salt, an alkali metal salt such as a sodium or a potassium salt, an alkaline earth metal salt such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine and salts thereof with amino acids such as arginine, lysine and the like.
  • a salt such as ammonium salt, an alkali metal salt such as a sodium or a potassium salt, an alkaline earth metal salt such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine and salts thereof with amino acids such as arginine, lysine and the like.
  • prodrug refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. They can, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug can also have improved solubility in pharmaceutical compositions over the parent drug or can demonstrate increased palpability or be easier to formulate.
  • Bupropion whose chemical name is ( ⁇ )-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone, is the active drug in the drugs marketed as ZYBAN® and WELLBUTRIN®, and is usually administered as a hydrochloride salt.
  • the term “bupropion” is used, it is understood that the term encompasses bupropion as a free base, or as a physiologically acceptable salt thereof, or as a bupropion metabolite or salt thereof.
  • the metabolites of bupropion suitable for inclusion in the methods and compositions described herein include the erythro- and threo-amino alcohols of bupropion, the erythro-amino diol of bupropion, and morpholinol metabolites of bupropion.
  • the metabolite of bupropion is ( ⁇ )-(2R*,3R*)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol.
  • the metabolite is ( ⁇ )-(2R*,3R*)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, while in other embodiments, the metabolite is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol.
  • the metabolite of bupropion is (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, which is known by its common name of radafaxine.
  • the scope of the present disclosure includes the above-mentioned metabolites of bupropion as a free base or as a physiologically acceptable salt thereof.
  • Controlled-release bupropion formulations of bupropion are known in the art. See, for example, U.S. Pat. No. 6,905,708, which discloses a once-daily dosage configured to deliver bupropion in vivo over a 6 to 12 hour period.
  • Olanzapine whose chemical name is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, is used as a psychotherapeutic agent primarily for the treatment of schizophrenia, acute manic episodes in bipolar disorder acute, maintenance treatment in bipolar disorder and agitation associated with both these disorders.
  • olanzapine it is understood that the term encompasses olanzapine as a free base, or as a physiologically acceptable salt thereof, or as a olanzapine metabolite or salt thereof.
  • Olanzapine displays linear kinetics. Its elimination half-life ranges from 21 to 54 hours. Steady state plasma concentrations are achieved in about a week. Olanzapine undergoes extensive first pass metabolism and bioavailability is not affected by food.
  • the psychotherapeutic agent may be selected from the group consisting of mirtazapine, setiptiline, paroxetine, venlafaxine, olanzapine, bupropion, risperidone, lamotrogine, risperidone, a lithium salt, valproic acid, and pharmaceutically acceptable salts or prodrugs thereof.
  • the psychotherapeutic agent is an antidepressant, an antimigrane, an antibipolar, an antimania drug, a mood stabilizer, or an antiepileptic. Examples of antidepressants include paroxetine, mirtazapine, and bupropion.
  • antibipolar drugs examples include lithium, valproate, carbamezepine, oxycarbamezepine, lamotrogine, tiagabine, olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, and benzodiazepines. Also included are pharmaceutically acceptable salts or prodrugs of these drugs, extended release or controlled release formulations of the above drugs, as well as combinations of the above drugs.
  • Fluoxetine is a selective serotonin reuptake inhibitor (SSRI), whose chemical name is N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine, is used primarily for the treatment of depression (including pediatric depression), obsessive-compulsive disorder (in both adult and pediatric populations), bulimia nervosa, panic disorder, premenstrual dysphoric disorder, hypochondriasis and body dysmorphic disorder.
  • SSRI selective serotonin reuptake inhibitor
  • Fluoxetine has a bioavailability of approximately 72%, and peak plasma concentrations are reached in 6 to 8 hours. It is highly bound to plasma proteins, mostly albumin. Its elimination half-life ranges from 1 to 3 days—after a single dose—to 4 to 6 days (after long-term use) in healthy adults, and is prolonged in those with liver disease. The half-life of norfluoxetine is longer (16 days after long-term use). Complete excretion of the drug may take several weeks.
  • the SSRI can be selected from fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, sibutramine, duloxetine, and venlafaxine, and pharmaceutically acceptable salts or prodrugs thereof.
  • the SSRI is fluoxetine or a pharmaceutically acceptable salt or prodrug thereof.
  • Fluoxetine has a physiological half life of about 24 hours, whereas that of naltrexone is about 1.5 hours. However their metabolites may demonstrate half-lives in excess of 24 hours. Thus, in some cases, it may be beneficial to administer one dose of fluoxetine per day in conjunction with two or three or more doses of naltrexone (discussed below) throughout the day. Naltrexone may also be in a time-release formulation where the dose is administered once a day, but naltrexone gradually enters the blood stream throughout the day, or in the course of a 12 hour period.
  • Symptoms of the obsessive compulsive disorders are inhibited in individuals being administered fluoxetine and naltrexone.
  • Adverse events associated with the obsessive compulsive disorders are reduced in individuals being administered fluoxetine and naltrexone.
  • the effects of administration of both fluoxetine and naltrexone on obsessive compulsive disorder are synergistic compared to effects of those expected by administration of fluoxetine and naltrexone alone.
  • Newer generation antidepressants include selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, and escitalopram), venlafaxine, duloxetine, nefazodone, mianserin setiptiline, viqualine trazodone, cianopramine, and mirtazapine.
  • selective serotonin reuptake inhibitors e.g., fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, and escitalopram
  • venlafaxine duloxetine
  • nefazodone nefazodone
  • mianserin setiptiline mianserin setiptiline
  • viqualine trazodone cianopramine
  • mirtazapine mirtazapine.
  • Phentermine is an example of a dopamine reuptake inhibitor with a chemical name 2-methyl-1-phenylpropan-2-amine and 2-methyl-amphetamine. Throughout the present disclosure, whenever the term “phentermine” is used, it is understood that the term encompasses phentermine as a free base, or as a physiologically acceptable salt thereof, or as a phentermine metabolite or salt thereof.
  • an antidiabetic comprises a biguanide, glucosidase inhibitor, insulin, meglitinide, sulfonylurea or a thiazolidinedione.
  • a biguanide comprises metformin hydrochloride.
  • a glucosidase inhibitor includes acarbose and miglitol.
  • insulin include human insulin, pork insulin, beef insulin, beef-pork insulin, insulin from different sources such as recombinant DNA and animal sources, as well as regular, NPH, and LENTE® types of insulin.
  • Other examples of insulin include mixtures of the various forms of insulin (e.g. NPH and regular human and pork insulin).
  • insulin examples include mixtures of Insulin Lispro Protamine and Insulin Injection (rDNA origin), a 50/50 (or a 70/30) mixture of Human Insulin Isophane Suspension and Human Insulin Injection, a 70/30 mixture of NPH Human Insulin Isophane Suspension and Human Insulin Injection (rDNA), insulin glargine, insulin lispro, insulin aspart, as well as insulin mixed with other ingredients such as zinc crystals or in a phosphate buffer.
  • Insulin may be from Saccharomyces cerevisiae or other sources. Examples of meglitinides include nateglinide and repaglinide.
  • sulfonylureas examples include glimepiride, glyburide, glibenclamide, gliquidone, gliclazide, chlorpropamide, tolbutamide, tolazamide and glipizide.
  • thiazolidinediones examples include rosiglitazone and pioglitazone. Also included are extended release formulations of the above drugs, as well as combinations of the above drugs and pharmaceutically acceptable salts or prodrugs thereof.
  • the antidiabetic is metformin.
  • Metformin whose chemical name is 1-(diaminomethylidene)-3,3-dimethyl-guanidine, is often used in the treatment of diabetes mellitus type 2, especially when accompanied obesity and insulin resistance. Metformin has also been proven to reduce the cardiovascular complications of diabetes.
  • the anticonvulsant is selected from the group consisting of zonisamide, topiramate, nembutal, lorazepam, clonazepam, clorazepate, tiagabine, gabapentin, fosphenyloin, phenyloin, carbamazepine, balproate, felbamate, lebetiracetam, oxcarbazepine, lamotrigine, methsuximide and ethosuxmide.
  • Zonisamide is a marketed anticonvulsant indicated as adjunctive therapy for adults with partial onset seizures. Without being bound by any particular theory, it is believed that the mechanism of antiepileptic activity appears to be: (1) sodium-channel blocking; and (2) reduction of inward T-type calcium occurrence.
  • zonisamide binds to the GABA/benzodiazepine receptor complex without producing change in chloride flux. Further, zonisamide facilitates serotonergic and dopaminergic neurotransmission and possesses a weak inhibitory effect on carbonic anhydrase.
  • Zonisamide has been shown to cause significant weight loss (comparable to marketed weight loss medications) in patients presenting primary obesity. It has been postulated that the affect of zonisamide on the CNS concentration of serotonin, dopamine and carbonic anhydrase is responsible for this effect. There is evidence that zonisamide increases serotonin and dopamine synthesis rates herein. There is further evidence suggesting that zonisamide stimulates dopamine D 2 receptors.
  • Zonisamide can be formulated in an immediate release, a controlled-release and/or sustained-release tablet or gel form. This allows a patient newly prescribed zonisamide to ramp up the dosage level over a period of several days. This increase in dosage form allows the patient to avoid some of the negative side effects that have been exhibited during the initial administration of zonisamide to a patient. Some of these initial side effects include a shock to the body. Although patients who start with a full dose of zonisamide will become acclimated to the dosage over a period of time, the negative side effects accompanying the initial shock to the body can be avoided with a method wherein dosages are increased over a period of several days.
  • a method of administering sustained-release zonisamide by increasing dosages over a period of time can reduce shock to the body while still having a maximum effect for prevention of weight gain and/or treatment of obesity.
  • the antidepressant and the anticonvulsant are administered more or less simultaneously. In other embodiments, the antidepressant is administered prior to the anticonvulsant. In yet other embodiments, the antidepressant is administered subsequent to the anticonvulsant.
  • the antidepressant and the anticonvulsant are administered individually.
  • the first compound and the anticonvulsant are covalently linked to each other such that they form a single chemical entity.
  • the single chemical entity is then digested and is metabolized into two separate physiologically active chemical entities, one of which is the antidepressant and the other one is the anticonvulsant.
  • compositions of the types found in the unit dosage packages of the present disclosure include forms suitable for packaging within a blister including gel capsules and tablets.
  • the anticonvulsant is a ⁇ -amino butyric acid (GABA) inhibitor, a GABA receptor antagonist or a GABA channel modulator.
  • GABA inhibitor it is meant a compound that reduces the production of GABA in the cells, reduces the release of GABA from the cells, or reduces the activity of GABA on its receptors, either by preventing the binding of GABA to GABA receptors or by minimizing the effect of such binding.
  • the GABA inhibitor may be a 5-HT1b agonist or another agent that inhibits the activity of NPY/AgRP/GABA neurons.
  • the GABA inhibitor may suppress the expression of the AgRP gene, or the GABA inhibitor may suppress the production or release of AgRP. It is, however, understood that a 5-HT1b agonist may inhibit the NPY/AgRP/GABA neuron (and therefore activate pro-opiomelanocortin (POMC) neurons) without acting as an inhibitor of the GABA pathway.
  • POMC pro-opiomelanocortin
  • the GABA inhibitor increases the expression of the POMC gene. In some of these embodiments, the GABA inhibitor increases the production or release of POMC protein. In certain other of these embodiments, the GABA inhibitor increases the activity on POMC expressing neurons.
  • the GABA inhibitor is topiramate.
  • Topiramate whose chemical name is 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate, is often used to treat epilepsy, Lennox-Gastaut syndrome (a disorder causing seizures and developmental delays), neuropathic pain, bipolar disorder, obesity including reduction of binge eating, alcoholism, Post Traumatic Stress Disorder, infantile spasm, bulimia nervosa, or obsessive-compulsive disorder or to assist smoking cessation or prevent migraines.
  • initial doses of topiramate are low and increased in slow steps. The usual initial dose is 25 to 50 mg daily in 2 single doses. Recommended increments vary, but are usually between 25 mg and 50 mg every 1 or 2 weeks. Common doses for maintenance treatment are 100 to 200 mg daily.
  • the opioid antagonist antagonizes a ⁇ -opioid receptor (MOP-R) in a mammal.
  • the mammal may be selected from the group consisting of mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, primates, such as monkeys, chimpanzees, and apes, and humans.
  • the opioid antagonist is selected from the group consisting of alvimopan, norbinaltorphimine, nalmefene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.
  • the opioid antagonist is a partial opioid agonist.
  • Compounds of this class have some agonist activity at opioid receptors. However, because they are weak agonists, they function as de-facto antagonists.
  • partial opioid agonists include pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.
  • Naltrexone (17-(cyclopropylmethyl)-4,5 ⁇ -epoxy-3,14-dihydroxymorphinan-6-one is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
  • ⁇ -subtype selective opioid antagonists such as naltrexone are also of considerable current interest as agents for the treatment of obesity (Glass, M. J.; Billington, C. J.; Levine, A. S. Neuropeptides 1999, 33, 350) and CNS disorders (Reneric, J. P.; Bouvard, M. P. CNS Drugs 1998, 10, 365).
  • Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade name REVIATM.
  • REVIATM is an immediate release formulation of naltrexone, with 50 mg strength. The maximum serum concentration of immediate release naltrexone is reached very rapidly, typically a T max of approximately 1 hour. Immediate release naltrexone can induce side effects such as nausea, which is attributable to the maximum blood plasma concentration levels (C max ).
  • oral dosage forms of naltrexone are effective to provide an AUC between about 75% to about 125% of 50 mg immediate release naltrexone tablets.
  • oral dosage forms of naltrexone provide an amount of a retardant excipient that is effective to provide a C max that is less than or equal to about 80% of the C max of 50 mg immediate release naltrexone tablets.
  • oral dosage forms described herein can formulate oral dosage forms described herein.
  • an oral dosage form that comprises an amount of naltrexone that is effective to provide an AUC between about 75% to about 125% of 50 mg immediate release naltrexone tablets, and an amount of an appropriate retardant excipient effective to provide a C max that is less than or equal to about 80% of the C max of 50 mg immediate release naltrexone tablets.
  • the skilled artisan could formulate an oral dosage form having a pharmacodynamic profile characterized by coverage of greater than or equal to about 80% of the opioid receptors in the hypothalamus.
  • a pharmaceutical formulation comprising sustained-release zonisamide and bupropion can be made in various ways, e.g., by intermixing granules or beads of sustained-release zonisamide with bupropion or sustained-release bupropion, then forming tablets from the mixture in the usual fashion.
  • a pharmaceutical formulation of zonisamide in combination with bupropion can be used to treat various conditions.
  • an embodiment provides a method for affecting weight loss, increasing energy expenditure, increasing satiety in an individual, and/or suppressing the appetite of an individual, comprising identifying an individual in need thereof and administering effective amounts of sustained-release zonisamide and bupropion.
  • the sustained-release zonisamide and bupropion are administered more or less simultaneously.
  • the sustained-release zonisamide is administered prior to the bupropion.
  • the sustained-release zonisamide is administered subsequent to the bupropion.
  • one of the compounds is administered while the other compound is being administered.
  • naltrexone comprises formulations of either immediate release naltrexone or sustained-release naltrexone.
  • a pharmaceutical formulation comprising sustained-release zonisamide and naltrexone can be made in various ways, e.g., by intermixing granules or beads of sustained-release zonisamide with naltrexone or sustained-release naltrexone, then forming tablets from the mixture in the usual fashion.
  • Sustained-release zonisamide pharmaceutical formulation can be used in combination with naltrexone to treat various conditions.
  • an embodiment provides a method for affecting weight loss, increasing energy expenditure, increasing satiety in an individual, and/or suppressing the appetite of an individual, comprising identifying an individual in need thereof and administering effective amounts of sustained-release zonisamide and naltrexone.
  • the sustained-release zonisamide and naltrexone are administered more or less simultaneously.
  • the sustained-release zonisamide is administered prior to the naltrexone.
  • the sustained-release zonisamide is administered subsequent to the naltrexone.
  • one of the compounds is administered while the other compound is being administered.
  • naltrexone comprises formulations of either immediate release naltrexone or sustained-release naltrexone.
  • bupropion comprises formulations of either immediate release or sustained-release bupropion.
  • a pharmaceutical formulation comprising both bupropion and naltrexone is used in various disclosed embodiments.
  • Sustained-release bupropion can be used in a pharmaceutical formulation with naltrexone to treat various conditions.
  • an embodiment provides a method for affecting weight loss, increasing energy expenditure, increasing satiety in an individual, and/or suppressing the appetite of an individual.
  • the method comprises identifying an individual in need thereof and administering effective amounts of sustained-release bupropion and naltrexone in a pharmaceutical formulation.
  • the bupropion and naltrexone are administered more or less simultaneously.
  • the bupropion is administered prior to the naltrexone.
  • the bupropion is administered subsequent to the naltrexone.
  • one of the compounds is administered while the other compound is being administered.
  • a method of treating a disease or condition comprises identifying a patient suffering from or at risk of said condition.
  • the disease or condition is selected from the group consisting of affecting weight loss, suppressing appetite and. treating an obesity-related condition.
  • the method comprises administering to a patient in need thereof a first dosage comprising a first drug and a second drug and administering a second dosage comprising the first drug and the second drug, wherein the second dosage comprises a different amount of the second drug than the first dosage.
  • the second dosage comprises a greater amount of the second drug than the amount of the second drug in the first dosage. In other embodiments the second dosage comprises a smaller amount of the second drug than the first dosage. In some embodiments the second dosage comprises a different amount of the first drug than the first dosage. In some embodiments the first drug comprises a greater amount in the second dosage than in the first dosage. In other embodiments the first drug comprises a smaller amount in the second dosage than in the first dosage. In some embodiments the first drug comprises a greater amount in the second dosage than in the first dosage and the second drug comprises a greater amount in the second dosage than in the first dosage.
  • the first drug comprises a greater amount in the second dosage than in the first dosage and the second drug comprises a smaller amount in the second dosage than in the first dosage. In some embodiments the first drug comprises a smaller amount in the second dosage than in the first dosage and the second drug comprises a smaller amount in the second dosage than in the first dosage.
  • the change in amount of the first and/or second drug can be continued in the third, fourth, fifth, sixth, seventh or more dosages, until the desired amount is reached, at which point the amount is maintained in subsequent doses.
  • the number of doses which have increasing or decreasing amounts of one drug can be different or the same as the number of doses which have increasing or decreasing amounts of the other drug.
  • the embodiments described herein are not limited to two drug combinations, but can include 3, 4, 5, 6, or more drugs, each independently increasing, decreasing or maintaining the amount of drug in dose.
  • the obesity-related condition is at least one selected from obesity, hypertension, diabetes, dyslipidaemia, hyperglycemia, weight gain associated with smoking cessation, and weight gain associated with use of a psychotherapeutic drug.
  • the second dosage comprises a greater amount of the second drug than the first dosage.
  • the first drug comprises an antidepressant.
  • the antidepressant comprises bupropion.
  • the bupropion comprises a controlled-release bupropion.
  • the controlled-release bupropion comprises a sustained-release bupropion.
  • the second drug comprises an anticonvulsant.
  • the anticonvulsant comprises zonisamide.
  • the zonisamide comprises a controlled-release zonisamide. In some embodiments the controlled-release zonisamide comprises a sustained-release zonisamide. In some embodiments the second drug comprises an opioid antagonist. In some embodiments the opioid antagonist comprises naltrexone. In some embodiments the naltrexone comprises a controlled-release naltrexone. In some embodiments the controlled-release naltrexone comprises a sustained-release naltrexone.
  • the first drug comprises an antidepressant and the second drug comprises an anticonvulsant.
  • the antidepressant comprises bupropion and the anticonvulsant comprises zonisamide.
  • the first drug comprises an antidepressant and the second drug comprises an opioid antagonist.
  • the antidepressant comprises bupropion and the opioid antagonist comprises naltrexone.
  • the method further comprises identifying the patient as being at risk of suffering an adverse side effect from administration of an anticonvulsant. In some embodiments the method further comprises identifying the patient as being at risk of suffering an adverse side effect from administration of an opioid antagonist.
  • the method further comprises opening a unit dosage package, the unit dosage package comprising the first dosage and the second dosage.
  • the unit dosage package comprises a blister pack.
  • the method further comprises administering a third dosage comprising the first drug and the second drug, wherein the third dosage comprises a greater amount of the second drug than the second dosage.
  • the method further comprises removing the first dosage and the second dosage from the unit dosage package.
  • administering the first dosage comprises administering a tablet that comprises the first drug and the second drug.
  • the tablet comprises a plurality of layers.
  • the tablet is a trilayer tablet.
  • a single blister comprises multiple drugs, wherein each drug is physically separated in physically separate forms, e.g, two or more tablets, capsules, pills, etc.
  • subsequent administrations of subsequent combinations of the first drug and the second drug are administered.
  • each subsequent combination the dosage of the second drug is increased, e.g., increasing the dosage of the second drug in each subsequent combination of the first drug and the second drug until a full dosage of the second drug is reached.
  • the individual can become accustomed to a full dosage combination of the first drug and the second drug through the above method and avoid many of the adverse side effects that could occur if the full dosage had been initially administered. Further, avoiding the adverse side effects reduces premature abandonment of the obesity medication and increases the probability of effecting weight loss in the individual.
  • a unit dosage package for a pharmaceutical formulation comprises a first unit dosage comprising a first drug and a second drug; a second unit dosage comprising the first drug and the second drug, wherein the second dosage comprises a different amount of the second drug than the first dosage; and a unit dosage package configured to hold the first unit dosage and the second unit dosage.
  • the second dosage comprises a greater amount of the second drug than the first dosage.
  • the first drug comprises an antidepressant.
  • the antidepressant comprises bupropion.
  • the bupropion comprises a sustained-release bupropion.
  • the second drug comprises an anticonvulsant.
  • the anticonvulsant comprises zonisamide.
  • the zonisamide comprises a sustained-release zonisamide.
  • the second drug comprises an opioid antagonist.
  • the opioid antagonist comprises naltrexone.
  • the naltrexone comprises a sustained-release naltrexone.
  • the first drug comprises an antidepressant and the second drug comprises an anticonvulsant.
  • the antidepressant comprises bupropion and the anticonvulsant comprises zonisamide.
  • the first drug comprises an antidepressant and the second drug comprises an opioid antagonist.
  • the antidepressant comprises bupropion and the opioid antagonist comprises naltrexone.
  • the unit dosage package comprises at least one blister and the at least one blister holds both the first drug and the second drug. In some embodiments the unit dosage package comprises a blister pack. In some embodiments at least one of the first unit dosage and the second unit dosage is a multi-layer tablet that comprises the first drug and the second drug. In some embodiments the multi-layer tablet is a trilayer tablet.
  • the multi-layer tablet is useful for the treatment of obesity and/or for affecting weight loss.
  • Some preferred embodiments comprise at least one of an antidepressant and an anticonvulsant.
  • Other preferred embodiments comprise at least one of an antidepressant and an opioid receptor antagonist.
  • Other preferred embodiments comprise at least one of an anticonvulsant and an opioid receptor antagonist.
  • Other preferred embodiments comprise at least one of an anticonvulsant and an antidiabetic.
  • one or more of the drugs comprises naltrexone and one or more of the drugs comprises fluoxetine. In another embodiment, one or more of the drugs comprises olanzapine and one or more of the drugs comprises zonisamide. In another embodiment, one or more of the drugs comprises metformin and one or more of the drugs comprises zonisamide. In another embodiment, one or more of drugs comprises phentermine and one or more of the drugs comprise topiramate.
  • the presence of one drug in a pharmaceutical formulation enhances the desired physiological effects and/or reduces undesired physiological effects of one or more other drugs in the pharmaceutical formulation. In some embodiments the presence of one or more drugs in a pharmaceutical formulation enhances the desired physiological effects of the drugs over the additive physiological effects of the one or more drugs in comparable pharmaceutical formulations when administered alone.
  • compositions of any drug mentioned herein can be configured in various ways and in a variety of dosage forms to modify a dissolution rate of the drug.
  • one type of controlled-release pharmaceutical formulation is a sustained-release pharmaceutical formulation.
  • Sustained-release pharmaceutical formulations can contain a variety of excipients, such as retardant excipients (also referred to as release modifiers) and/or fillers that are selected and incorporated into the formulation in such a way as to slow the dissolution rate of the formulation (and thereby slow the dissolution and/or release of the zonisamide) under in vivo conditions as compared to an otherwise comparable immediate-release formulation.
  • a “comparable” immediate-release formulation is one that is substantially identical to the controlled-release formulation, except that that it is configured to provide immediate-release instead of controlled-release under substantially identical conditions.
  • immediate-release is used herein to specify a formulation that is not configured to alter the dissolution profile of the active ingredient (e.g., zonisamide, bupropion, naltrexone, olanzapine, phentermine, topiramate, metformin, fluoxetine).
  • an immediate-release pharmaceutical formulation may be a pharmaceutical formulation that does not contain ingredients that have been included for the purpose of altering the dissolution profile.
  • An immediate-release formulation thus includes drug formulations that take less than 30 minutes for substantially complete dissolution of the drug in a standard dissolution test.
  • a “standard dissolution test,” as that term is used herein, is a test conducted according to United States Pharmacopeia 24th edition (2000) (USP 24), pp.
  • controlled-release is used herein in its ordinary sense and thus includes pharmaceutical formulations that are combined with ingredients to alter their dissolution profile.
  • a “sustained-release” formulation is a type of controlled-release formulation, wherein ingredients have been added to a pharmaceutical formulation such that the dissolution profile of the active ingredient is extended over a longer period of time than that of an otherwise comparable immediate-release formulation.
  • a controlled-release formulation thus includes drug formulations that take 30 minutes or longer for substantially complete dissolution of the drug in a standard dissolution test, conditions which are representative of the in vivo release profile.
  • a method of packaging a combination of bupropion and at least one of zonisamide and naltrexone comprises providing a unit dosage package that holds the bupropion and the at least one of the zonisamide and the naltrexone; and packaging administration instructions with the unit dosage package in a unit dosage package.
  • the bupropion comprises a sustained-release bupropion.
  • the zonisamide comprises a sustained-release zonisamide.
  • the naltrexone comprises a sustained-release naltrexone.
  • packaging administration instructions in the unit dosage package comprises printing instructions onto the unit dosage package.
  • the unit dosage package comprises a blister pack.
  • the method is realized by a medical professional e.g., a physician or a hospital employee.
  • the medical professional administers each dosage, a “unit dosage” (as defined herein), of the first drug and the second drug to the individual in need of such treatment.
  • Each succeeding unit dosage combination contains an increased dosage of the second drug until a full dosage of the first drug in combination with the second drug is reached.
  • the medical professional employs a unit dosage package.
  • the unit dosage package contains a number of “unit dosages”, each representing a single administration of a particular pharmaceutical formulation.
  • the pharmaceutical formulation comprises a specific combination of a first drug and a second drug.
  • the pharmaceutical formulation may be a single pill, capsule, tablet, etc. or may be a plurality of pills, capsules, tablets, etc.
  • Each successive pharmaceutical formulation in a unit dosage package ramps up the dosage of the second drug until a full dosage is reached. In this manner, at a first administration a medical professional removes a first pharmaceutical formulation dosage from the unit dosage package and administers the first dosage to an individual.
  • the medical professional removes a second pharmaceutical formulation dosage from the unit dosage package and administers the second dosage to the individual.
  • the medical professional removes and administers successive pharmaceutical formulation dosages until a full dosage of the second drug in combination with the first drug is reached. The medical professional is thus able to perform one embodiment of the method.
  • Another embodiment provides a system for performing the method by an individual without the constant supervision of a medical professional.
  • An individual is provided with a unit dosage package comprising a unit dosage package.
  • the unit dosage package comprises a number of dosages, each dosage representing a pharmaceutical formulation.
  • the pharmaceutical formulations comprise varying combinations of a first drug and a second drug.
  • the dosages are arranged within the unit dosage package so that each successive pharmaceutical formulation contains increased amounts of the second drug in combination with constant amounts of the first drug e.g., until a full dosage of the second drug is reached.
  • the individual removes the first pharmaceutical formulation from the unit dosage package and ingests it.
  • each successive dosage is labeled sequentially with numbers or letters, or a combination of the two. In some embodiments each successive dosage corresponds to a day or time label.
  • the second pharmaceutical formulation and each successive formulation in the unit dosage package comprise an increased amount of the second drug until a full dosage is reached.
  • Some embodiments of a unit dosage package also comprise instructions to the individual for administration of each successive pharmaceutical formulation. The individual becomes accustomed to increased pharmaceutical formulations dosages. Thus, the individual can use the unit dosage package to decrease or avoid many of the initial adverse side effects associated with administering a full dosage combination of the first drug and the second drug to affect weight loss.
  • a unit dosage package that designates a particular length of time for administration of one or more drugs.
  • a particular unit dosage package may comprise a month of unit dosages.
  • Another unit dosage package may comprise a week of unit dosages.
  • Another unit dosage package may comprise two or more days of unit dosages.
  • a unit dosage package may also comprise detachable strips representing smaller lengths of time.
  • a unit dosage package representing two or more weeks may comprise two or more portions that may be detached to form individual unit dosage packages.
  • unit dosage packages include those that accommodate pharmaceutical formulations representing daily unit dosage forms in a contiguous, sequential arrangement which, if properly used according to instructions packaged therewith, cause the proper formulation to be administered at the appropriate time.
  • a unit dosage package can comprise individual blister pods (“blisters”) for the storage in each of a single unit dosage form. At the appropriate time the unit dosage form is manually dispensed therefrom through a frangible retaining layer. Storage of other unit dosage forms is not affected by such dispensing.
  • Appropriate notations are placed on the unit dosage package or the unit dosage package, if desired, to guide or instruct the user thereof in the proper use of the pharmaceutical formulations contained therein. For example, day of the week, miscellaneous instructions, etc., are provided, if so desired.
  • a unit dosage package comprises a number of blisters.
  • Blisters comprise unit dosages. Unit dosages of pharmaceutical formulations comprising at least a first drug and a second drug are thus administered from the unit dosage package.
  • a single blister contains a unit dosage of both the first drug and the second drug.
  • a single blister contains either a unit dosage of a first drug or a unit dosage of a second drug. (In the latter case a corresponding blister can contain a corresponding dosage of the other.)
  • a unit dosage package is a blister pack, a pill box or a medication dispenser.
  • pill boxes include a wallet card pill carrier, a key ring pill box, a capsule shaped pill box, a hollow necklace dispenser, a weekly organizer, an organizer cube, an airtight box and a hollow pocket watch.
  • medication dispensers include certain types of unit dosage packages that hold certain medications in a specific order for accurate administration.
  • a unit dosage package has compartments holding specific unit dosages and/or combinations of pharmaceutical formulations including prescribed medications suitable for administration to a patient.
  • Some unit dosage packages include instructions for medication administration.
  • the dosages are provided at least once, twice or three times a day for a set period, which can be at least, at least about, less than, less than about, equal to or between any range within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive days or at least, at least about, less than, less than about, equal to or between any range within of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive weeks or at least, at least about, less than, less than about, equal to or between any range within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 consecutive months.
  • the amount of drug in any pharmaceutical formulation described herein includes amounts of at least, at least about, less than, less than about, equal to or between any range within 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1500, 2000, 3000, 4000 or 5000 mg.
  • a unit dosage package for a pharmaceutical formulation comprises a first unit dosage comprising a first drug and a second drug, a second unit dosage comprising the first drug and the second drug, wherein the second unit dosage comprises a different amount of the second drug than the first unit dosage and a unit dosage package configured to hold the first unit dosage and the second unit dosage.
  • the second unit dosage comprises a greater amount of the second drug than the first unit dosage.
  • the first drug or the second drug comprises an antidepressant.
  • the antidepressant comprises bupropion.
  • the bupropion comprises a sustained-release bupropion.
  • the first drug or the second drug comprises an anticonvulsant.
  • the anticonvulsant comprises zonisamide.
  • the zonisamide comprises a sustained-release zonisamide.
  • the first drug or the second drug comprises an opioid antagonist.
  • the opioid antagonist comprises naltrexone.
  • the first drug comprises bupropion and the second drug comprises zonisamide. In some embodiments the first drug comprises bupropion and the second drug comprises naltrexone. In some embodiments the first drug comprises fluoxetine and the second drug comprises naltrexone. In some embodiments the first drug comprises olanzapine and the second drug comprises zonisamide. In some embodiments the first drug comprises antidiabetic and the second drug comprises zonisamide. In some embodiments the antidiabetic comprises metformin. In some embodiments the first drug comprises topiramate and the second drug comprises phentermine. In some embodiments the unit dosage package comprises a blister and the blister holds both the first drug and the second drug.
  • the first drug and the second drug are selected from the group consisting of zonisamide, bupropion, naltrexone, phentermine, topiramate, metformin, olanzapine, fluoxetine, and any combinations, prodrugs or salts thereof.
  • the first drug and the second drug are part of a single physical form.
  • the single physical form is a multi-layer tablet.
  • the multi-layer tablet is a trilayer tablet.
  • the unit dosage package comprises a first blister and a second blister, wherein the first blister holds the first drug and the second blister holds the second drug.
  • the unit dosage package comprises a blister pack.
  • a method of providing a pharmaceutical formulation to a patient comprises providing a unit dosage package for a pharmaceutical formulation, wherein the unit dosage package is configured to hold a first unit dosage and a second unit dosage, wherein the first unit dosage comprises a first drug and a second drug, wherein the second unit dosage comprises the first drug and the second drug, and wherein the second unit dosage comprises a different amount of the second drug than the first unit dosage.
  • the method further comprises identifying a patient with an obesity related condition, wherein the obesity-related condition is selected from the group consisting of obesity, hypertension, diabetes, dyslipidaemia, weight gain associated with smoking cessation and weight gain associated with use of a psychotherapeutic drug.
  • the second dosage comprises a greater amount of the second drug than the first dosage.
  • the first drug or the second drug comprises an antidepressant. In some embodiments the first drug or the second drug comprises an anticonvulsant. In some embodiments the first drug or the second drug comprises an opioid antagonist. In some embodiments the first drug or the second drug comprises an antidiabetic. In some embodiments the first drug and the second drug are selected from the group consisting of zonisamide, bupropion, naltrexone, phentermine, topiramate, antidiabetic, olanzapine, fluoxetine, and any combinations, prodrugs or salts thereof.
  • the method further comprises identifying the patient as being at risk of suffering an adverse side effect from administration of an anticonvulsant. In some embodiments the method further comprises identifying the patient as being at risk of suffering an adverse side effect from administration of an opioid antagonist. In some embodiments the method further comprises opening a unit dosage package, the unit dosage package comprising the first dosage and the second dosage. In some embodiments the unit dosage package comprises a blister pack.
  • the unit dosage package comprises a third unit dosage and, wherein the third dosage comprises a greater amount of the second drug than the second dosage.
  • providing the unit dosage package comprises removing the first dosage and the second dosage from the unit dosage package.
  • providing a unit dosage package comprises administering a tablet that comprises the first drug and the second drug to the patient, wherein the tablet comprises a plurality of layers. In some embodiments the tablet is a trilayer tablet.
US11/937,367 2006-11-09 2007-11-08 Methods for administering weight loss medications Abandoned US20080110792A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/937,367 US20080110792A1 (en) 2006-11-09 2007-11-08 Methods for administering weight loss medications
US12/838,364 US8722085B2 (en) 2006-11-09 2010-07-16 Methods for administering weight loss medications
US14/220,349 US9125868B2 (en) 2006-11-09 2014-03-20 Methods for administering weight loss medications
US14/844,476 US20160193152A1 (en) 2006-11-09 2015-09-03 Methods for administering weight loss medications
US16/101,853 US10307376B2 (en) 2006-11-09 2018-08-13 Methods for administering weight loss medications
US16/428,069 US20190282503A1 (en) 2006-11-09 2019-05-31 Methods For Administering Weight Loss Medications
US16/938,443 US20200352863A1 (en) 2006-11-09 2020-07-24 Methods For Administering Weight Loss Medications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86515906P 2006-11-09 2006-11-09
US11/937,367 US20080110792A1 (en) 2006-11-09 2007-11-08 Methods for administering weight loss medications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/838,364 Continuation US8722085B2 (en) 2006-11-09 2010-07-16 Methods for administering weight loss medications

Publications (1)

Publication Number Publication Date
US20080110792A1 true US20080110792A1 (en) 2008-05-15

Family

ID=39402403

Family Applications (7)

Application Number Title Priority Date Filing Date
US11/937,367 Abandoned US20080110792A1 (en) 2006-11-09 2007-11-08 Methods for administering weight loss medications
US12/838,364 Active US8722085B2 (en) 2006-11-09 2010-07-16 Methods for administering weight loss medications
US14/220,349 Active US9125868B2 (en) 2006-11-09 2014-03-20 Methods for administering weight loss medications
US14/844,476 Abandoned US20160193152A1 (en) 2006-11-09 2015-09-03 Methods for administering weight loss medications
US16/101,853 Active US10307376B2 (en) 2006-11-09 2018-08-13 Methods for administering weight loss medications
US16/428,069 Abandoned US20190282503A1 (en) 2006-11-09 2019-05-31 Methods For Administering Weight Loss Medications
US16/938,443 Pending US20200352863A1 (en) 2006-11-09 2020-07-24 Methods For Administering Weight Loss Medications

Family Applications After (6)

Application Number Title Priority Date Filing Date
US12/838,364 Active US8722085B2 (en) 2006-11-09 2010-07-16 Methods for administering weight loss medications
US14/220,349 Active US9125868B2 (en) 2006-11-09 2014-03-20 Methods for administering weight loss medications
US14/844,476 Abandoned US20160193152A1 (en) 2006-11-09 2015-09-03 Methods for administering weight loss medications
US16/101,853 Active US10307376B2 (en) 2006-11-09 2018-08-13 Methods for administering weight loss medications
US16/428,069 Abandoned US20190282503A1 (en) 2006-11-09 2019-05-31 Methods For Administering Weight Loss Medications
US16/938,443 Pending US20200352863A1 (en) 2006-11-09 2020-07-24 Methods For Administering Weight Loss Medications

Country Status (14)

Country Link
US (7) US20080110792A1 (ja)
EP (1) EP2088998A2 (ja)
JP (1) JP2010508997A (ja)
KR (6) KR20180066272A (ja)
CN (1) CN101573103A (ja)
AR (1) AR063958A1 (ja)
AU (1) AU2007319472B2 (ja)
CA (1) CA2668885C (ja)
CL (1) CL2007003246A1 (ja)
IL (1) IL198578A0 (ja)
MX (3) MX343867B (ja)
RU (1) RU2009116834A (ja)
TW (1) TW200829235A (ja)
WO (1) WO2008060964A2 (ja)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113580A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100331420A1 (en) * 2009-06-26 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110098289A1 (en) * 2002-05-17 2011-04-28 Gadde Kishore M Method for treating obesity
WO2011085331A1 (en) 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
WO2012075453A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
WO2012155091A1 (en) * 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
US20130245056A1 (en) * 2010-12-03 2013-09-19 Orexigen Therapeutics, Inc. Increasing drug bioavailability in naltrexone therapy
WO2013184837A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8722085B2 (en) 2006-11-09 2014-05-13 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8815889B2 (en) 2005-11-22 2014-08-26 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US20150196522A1 (en) * 2010-02-25 2015-07-16 Northwestern University Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US20150352062A1 (en) * 2013-02-28 2015-12-10 Tadmor Shalon Methods and systems for treating overweight individuals
US9931273B2 (en) 2014-11-03 2018-04-03 Multi Packaging Solutions Uk Limited Packaging
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
CN105468895A (zh) 2006-05-02 2016-04-06 普罗透斯数字保健公司 患者定制的治疗方案
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
CN101686800A (zh) 2007-02-01 2010-03-31 普罗秋斯生物医学公司 可摄入事件标记器系统
CA2676280C (en) 2007-02-14 2018-05-22 Proteus Biomedical, Inc. In-body power source having high surface area electrode
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
EP2192946B1 (en) 2007-09-25 2022-09-14 Otsuka Pharmaceutical Co., Ltd. In-body device with virtual dipole signal amplification
AU2009268827B2 (en) 2008-07-08 2013-10-24 Proteus Digital Health, Inc. Ingestible event marker data framework
CA2750158A1 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
EP2734973A4 (en) 2011-07-21 2015-07-01 Proteus Digital Health Inc MOBILE COMMUNICATION DEVICE, SYSTEM AND METHOD
WO2013078416A2 (en) * 2011-11-23 2013-05-30 Proteus Digital Health, Inc. Apparatus, system, and method to promote behavior change based on mindfulness methodologies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
WO2017087373A1 (en) * 2015-11-16 2017-05-26 Actavis Elizabeth Llc Modified release abuse deterrent tablet
KR102215238B1 (ko) 2016-07-22 2021-02-22 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 이벤트 마커의 전자기 감지 및 검출
WO2020172484A1 (en) * 2019-02-21 2020-08-27 Accoy Pharmaceuticals, Inc. Point of care pharmacy app controlled blister pack drug dispenser
WO2021053542A1 (en) * 2019-09-20 2021-03-25 Dr. Reddy’S Laboratories Limited Pharmaceutical compositions for obesity management
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
US11759393B2 (en) * 2020-11-09 2023-09-19 Hassan Zakaria Prescription medicine packaging system and method for using same to provide range of compliance options
CN113069438A (zh) * 2021-04-01 2021-07-06 沈阳欣瑞制药有限公司 含有二甲双胍和安非他酮的药物组合物及其用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3942641A (en) * 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4295567A (en) * 1978-11-10 1981-10-20 Beecham Group Limited Medicament container
US6541478B1 (en) * 1996-03-13 2003-04-01 Yale University Smoking cessation treatments using naltrexone and related compounds
US20040033965A1 (en) * 2002-05-17 2004-02-19 Gadde Kishore M. Method for treating obesity
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US6905708B2 (en) * 1999-02-26 2005-06-14 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20050181070A1 (en) * 2004-01-13 2005-08-18 Gadde Kishore M. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
US20060058293A1 (en) * 2004-08-03 2006-03-16 Eckard Weber Combination of bupropion and a second compound for affecting weight loss
US20060079501A1 (en) * 2004-01-13 2006-04-13 Krishnan K R R Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7422110B2 (en) * 2003-07-16 2008-09-09 Allergan, Inc. Titration/compliance pack with increasing doses

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US4089855A (en) * 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4218433A (en) 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4895845A (en) * 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
NL8800823A (nl) 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
ATE93721T1 (de) 1987-05-04 1993-09-15 Lilly Co Eli Verwendung von fluoxetin zur behandlung des diabetes.
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
AU5439890A (en) 1989-05-09 1990-11-29 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
FR2657350B1 (fr) 1990-01-19 1992-05-15 Centre Nat Rech Scient Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
CA2197554A1 (en) 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
EP0844870B1 (en) 1995-08-17 2001-11-21 Csir Controlled release products
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
DK0914097T3 (da) * 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DK0934069T3 (da) 1996-05-07 2007-03-19 Pliva Istrazivanje I Razvoj D Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DK0915697T3 (da) 1996-06-28 2003-01-27 Ortho Mcneil Pharm Inc Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
KR100508393B1 (ko) 1997-12-26 2005-08-17 다이닛본 세이야꾸 가부시끼가이샤 신경변성질환 치료약
BR9907203A (pt) 1998-01-21 2000-10-17 Glaxo Group Ltd "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. "
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) * 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
WO2000050020A2 (en) 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20030035840A1 (en) * 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6387956B1 (en) * 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
EP1204626B1 (en) * 1999-04-01 2008-01-16 Esperion Therapeutics Inc. Ether compounds, compositions, and uses thereof
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
EP1187603B1 (en) 1999-06-14 2007-08-08 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6034322A (en) * 1999-07-01 2000-03-07 Space Systems/Loral, Inc. Solar cell assembly
DE60020613T2 (de) 1999-07-01 2006-03-16 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
WO2001026641A2 (en) 1999-10-13 2001-04-19 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
US6410736B1 (en) * 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
US20030144271A1 (en) 2000-01-22 2003-07-31 Albert Shulman Methods for the treatment of substance abuse
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US20020090615A1 (en) 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
ATE326222T1 (de) * 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
WO2001078725A2 (en) 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
JPWO2001078681A1 (ja) 2000-04-17 2004-01-08 山之内製薬株式会社 薬物動態学的な薬物相互作用を回避する薬物送達システム及びその方法
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2408106A1 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
DE60134251D1 (de) * 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
EP1333887B1 (en) * 2000-10-30 2006-08-02 Ortho-McNeil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
EP1404342A1 (en) 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US6926907B2 (en) 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6462237B1 (en) 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
EP1414418A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
KR20040029405A (ko) 2001-08-06 2004-04-06 유로-셀티크 소시에떼 아노뉨 방출성 및 격리된 길항제와 오피오이드 효능제의 제제
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
JP2003060134A (ja) 2001-08-17 2003-02-28 Polymatech Co Ltd 熱伝導性シート
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030133982A1 (en) 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
AU2003242527B2 (en) 2002-05-17 2008-10-23 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
EP1534074A4 (en) 2002-07-18 2008-01-09 Merck & Co Inc POLYTHERAPY FOR THE TREATMENT OF OBESITY
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US6702097B1 (en) * 2002-09-04 2004-03-09 Owens-Brockway Glass Container Inc. Method of and apparatus for transferring articles from a fixed position to a moving conveyor
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
JP2006507251A (ja) 2002-09-13 2006-03-02 エーザイ株式会社 振せんの治療方法
EP1556091A1 (en) 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040092504A1 (en) * 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
JP2006514986A (ja) 2002-12-13 2006-05-18 シラグ・アクチエンゲゼルシヤフト トラマドールおよびトピラメートを含んでなる制御放出調製物
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
US20040158194A1 (en) 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
CA2522471A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05012317A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
EP1626722A1 (en) 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050019385A1 (en) * 2003-07-21 2005-01-27 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
CA2524300C (en) 2003-08-08 2008-10-28 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
KR100965580B1 (ko) * 2003-08-21 2010-06-23 엘지디스플레이 주식회사 액정표시장치와 그의 구동방법
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
CN1835759B (zh) 2003-08-21 2012-05-02 达切斯内公司 微量营养素补充剂
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
PT1663229E (pt) 2003-09-25 2010-07-13 Euro Celtique Sa CombinaãŽes farmac—uticas de hidrocodona e naltrexona
US20050112198A1 (en) 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
WO2005065645A2 (en) 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2005079773A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
SE0400378D0 (sv) 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
CA2558535A1 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2005107806A1 (en) 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
ES2539969T3 (es) 2004-08-25 2015-07-07 Essentialis, Inc. Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005302669A1 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as CB1 antagonists
US20080009477A1 (en) 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
US20060246131A1 (en) 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
US20060276412A1 (en) 2005-05-31 2006-12-07 Gary Tollefson Methods and compositions for managing psychotic disorders
US20070021352A1 (en) 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
WO2007016108A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20070048237A1 (en) * 2005-08-26 2007-03-01 Song Leila S Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
TWI425944B (zh) 2005-11-28 2014-02-11 Orexigen Therapeutics Inc 唑尼沙胺（ｚｏｎｉｓａｍｉｄｅ）之持續釋放調配物
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
HUE032156T2 (en) * 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
WO2008011150A1 (en) * 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
EP2646011B1 (en) 2010-12-03 2017-08-16 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
ES2924024T3 (es) 2012-06-06 2022-10-04 Nalpropion Pharmaceuticals Llc Composición para su uso en un método para el tratamiento del sobrepeso y la obesidad en pacientes con alto riesgo cardiovascular
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3942641A (en) * 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4295567A (en) * 1978-11-10 1981-10-20 Beecham Group Limited Medicament container
US4295567B1 (en) * 1978-11-10 1997-09-09 Beecham Grp Ltd Medicament container
US6541478B1 (en) * 1996-03-13 2003-04-01 Yale University Smoking cessation treatments using naltrexone and related compounds
US6905708B2 (en) * 1999-02-26 2005-06-14 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US20050143322A1 (en) * 2002-05-17 2005-06-30 Gadde Kishore M. Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20060009514A1 (en) * 2002-05-17 2006-01-12 Gadde Kishore M Method for treating obesity
US20040198668A1 (en) * 2002-05-17 2004-10-07 Duke University Method for treating obesity
US20050137144A1 (en) * 2002-05-17 2005-06-23 Gadde Kishore M. Method for treating obesity
US20040033965A1 (en) * 2002-05-17 2004-02-19 Gadde Kishore M. Method for treating obesity
US20040254208A1 (en) * 2003-04-29 2004-12-16 Eckard Weber Compositions for affecting weight loss
US20060142290A1 (en) * 2003-04-29 2006-06-29 Eckard Weber Compositions for affecting weight loss
US7422110B2 (en) * 2003-07-16 2008-09-09 Allergan, Inc. Titration/compliance pack with increasing doses
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050181070A1 (en) * 2004-01-13 2005-08-18 Gadde Kishore M. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060079501A1 (en) * 2004-01-13 2006-04-13 Krishnan K R R Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20050277579A1 (en) * 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
US20060058293A1 (en) * 2004-08-03 2006-03-16 Eckard Weber Combination of bupropion and a second compound for affecting weight loss

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110098289A1 (en) * 2002-05-17 2011-04-28 Gadde Kishore M Method for treating obesity
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8815889B2 (en) 2005-11-22 2014-08-26 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US8722085B2 (en) 2006-11-09 2014-05-13 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8318788B2 (en) 2006-11-09 2012-11-27 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113580A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331420A1 (en) * 2009-06-26 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
WO2011085331A1 (en) 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US10322121B2 (en) 2010-01-11 2019-06-18 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US11033543B2 (en) 2010-01-11 2021-06-15 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
US20150196522A1 (en) * 2010-02-25 2015-07-16 Northwestern University Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
EP2646031A1 (en) * 2010-12-03 2013-10-09 Orexigen Therapeutics, Inc. Increasing drug bioavailability in naltrexone therapy
WO2012075453A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
EP4349369A2 (en) 2010-12-03 2024-04-10 Nalpropion Pharmaceuticals LLC Increasing drug bioavailability in naltrexone therapy
EP2646031A4 (en) * 2010-12-03 2014-04-23 Orexigen Therapeutics Inc INCREASING THE BIOAVAILABILITY OF REMEDIES IN NRLREXON THERAPY
US20130245056A1 (en) * 2010-12-03 2013-09-19 Orexigen Therapeutics, Inc. Increasing drug bioavailability in naltrexone therapy
EP3884947A1 (en) 2010-12-03 2021-09-29 Nalpropion Pharmaceuticals LLC Increasing drug bioavailability in naltrexone therapy
EP3222280A1 (en) 2010-12-03 2017-09-27 Orexigen Therapeutics, Inc. Increasing drug bioavailability in naltrexone therapy
WO2012155091A1 (en) * 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
EP3730132A1 (en) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
WO2013184837A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US10403170B2 (en) 2012-06-06 2019-09-03 Nalpropion Pharmaceuticals, Inc. Methods of treating overweight and obesity
US20150352062A1 (en) * 2013-02-28 2015-12-10 Tadmor Shalon Methods and systems for treating overweight individuals
WO2015085044A1 (en) 2013-12-06 2015-06-11 Orexigen Therapeutics, Inc. Compositions and methods for reducing major adverse cardiovascular events
US10231964B2 (en) 2013-12-06 2019-03-19 Nalpropion Pharmaceuticals, Inc. Compositions and methods for weight loss in at risk patient populations
US10231962B2 (en) 2013-12-06 2019-03-19 Nalpropion Pharmaceuticals, Inc. Compositions and methods for reducing major adverse cardiovascular events
US9801875B2 (en) 2013-12-06 2017-10-31 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP4005571A1 (en) 2013-12-06 2022-06-01 Nalpropion Pharmaceuticals LLC Compositions and methods for reducing major adverse cardiovascular events
US9119850B2 (en) 2013-12-06 2015-09-01 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9931273B2 (en) 2014-11-03 2018-04-03 Multi Packaging Solutions Uk Limited Packaging

Also Published As

Publication number Publication date
US20190282503A1 (en) 2019-09-19
WO2008060964A3 (en) 2008-09-12
MX2023006414A (es) 2023-06-15
MX343867B (es) 2016-11-25
EP2088998A2 (en) 2009-08-19
IL198578A0 (en) 2010-02-17
US20140322318A1 (en) 2014-10-30
AU2007319472B2 (en) 2013-01-17
CL2007003246A1 (es) 2008-03-24
US20180360760A1 (en) 2018-12-20
JP2010508997A (ja) 2010-03-25
KR20180066272A (ko) 2018-06-18
US20110059170A1 (en) 2011-03-10
WO2008060964A2 (en) 2008-05-22
TW200829235A (en) 2008-07-16
AU2007319472A2 (en) 2009-07-02
AR063958A1 (es) 2009-03-04
US9125868B2 (en) 2015-09-08
US10307376B2 (en) 2019-06-04
KR20090090316A (ko) 2009-08-25
KR20160072276A (ko) 2016-06-22
US20200352863A1 (en) 2020-11-12
RU2009116834A (ru) 2010-12-20
KR20150082689A (ko) 2015-07-15
CA2668885C (en) 2016-08-02
KR20140088619A (ko) 2014-07-10
AU2007319472A1 (en) 2008-05-22
KR20170077291A (ko) 2017-07-05
MX2009004871A (es) 2009-06-16
CN101573103A (zh) 2009-11-04
CA2668885A1 (en) 2008-05-22
US20160193152A1 (en) 2016-07-07
US8722085B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
US20200352863A1 (en) Methods For Administering Weight Loss Medications
US8088786B2 (en) Layered pharmaceutical formulations
AU2017200230B2 (en) Unit Dosage Package and Methods for Administering Weight Loss Medications

Legal Events

Date Code Title Description
AS Assignment

Owner name: OREXIGEN THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCKINNEY, ANTHONY;TOLLEFSON, GARY;WEBER, ECKARD;AND OTHERS;REEL/FRAME:020524/0424;SIGNING DATES FROM 20080202 TO 20080204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGEN

Free format text: SECURITY AGREEMENT;ASSIGNOR:OREXIGEN THERAPEUTICS, INC.;REEL/FRAME:038180/0021

Effective date: 20160321